Abstract
We assessed a schedule alternating 4 FOLFOX and 4 FOLFIRI cycles in 39 patients with 5-FU resistant metastatic colorectal cancer. Patients alternatively received 4 FOLFOX-6 cycles (oxaliplatin 100 mg/m(2), leucovorin 200 mg/m(2) d1 followed by bolus 400 mg/m(2) 5-FU and by a 46-hour 2,400 mg/m(2) 5-FU infusion, every 2 weeks), and 4 FOLFIRI cycles (oxaliplatin replaced by irinotecan 180 mg/m(2) d1) until progression or limiting toxicity. Eigteen patients achieved an objective response (46.1 percent). Median progression-free and overall survivals were 8.8 and 18.7 months, respectively. Only 2 patients (5.1 percent) had Grade 3 oxaliplatin-related sensory-neuropathy. This schedule had so promising efficacy and safety.
Publication types
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / mortality
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / analogs & derivatives
-
Camptothecin / therapeutic use
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / mortality
-
Drug Resistance, Neoplasm
-
Female
-
Fluorouracil / therapeutic use
-
Humans
-
Leucovorin / therapeutic use
-
Male
-
Middle Aged
-
Neoplasm Metastasis / drug therapy
-
Organoplatinum Compounds / therapeutic use
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Organoplatinum Compounds
-
Leucovorin
-
Fluorouracil
-
Camptothecin
Supplementary concepts
-
Folfox protocol
-
IFL protocol